Elutiq GmbH
Through 'in-bone micro-pharmacies' targeting compromised bone biology.
Drug-eluting solutions enabling single-stage treatment of orthopedic infections and bone defects.
1
Single-stage treatment strategy replacing costly staged care.
>25x
MIC maintained in prototype release testing.
4-6
Weeks of clinically relevant extendable release.
$30-50K
Current total episode cost burden.
Complex orthopedic infections and large bone defects remain among the most difficult challenges in musculoskeletal medicine. The current standard of care often requires two or more surgical procedures combined with prolonged systemic antibiotic therapy.
This increases operating room utilization, extends recovery timelines, exposes patients to systemic side effects, and significantly increases total episode-of-care costs for hospitals and healthcare systems.
Open Fractures (Gustilo II-III): severe traumatic fractures frequently present with contaminated bone defects and a high risk of infection. Effective local infection control combined with structural bone repair is critical for limb salvage.
Chronic Osteomyelitis: persistent bone infections often require multiple surgeries, prolonged hospitalization, and long-term antibiotic therapy, with high recurrence rates and significant healthcare costs.
Periprosthetic Joint Infection: infections around joint replacements are among the most devastating complications in orthopedic surgery, frequently requiring staged revision procedures and extended treatment timelines.
Infected Non-Union: combined failure of bone healing combined with infection represents a complex clinical scenario where infection eradication and biological bone regeneration must be addressed simultaneously.
Elutiq GmbH is transforming orthopedic surgery by creating 'in-bone micro-pharmacies', a platform designed for scalable regulatory pathways and broad orthopedic indications, where surgeons can balance infection management, structural repair, and regeneration within a single treatment strategy.
We combine advanced nanomedicine and pharmacological delivery technologies with clinically proven allograft biology, creating solutions aligned with surgeon workflow, hospital economics, and regulatory feasibility.
Why now
Orthopedic infections and complex bone defects are rising globally due to aging populations, increasing trauma cases, and the rapid growth of joint replacement surgeries. Antimicrobial resistance and hospital cost pressures are forcing a shift toward more efficient surgical solutions. Elutiq's drug-eluting bone graft platform addresses this convergence by enabling infection control and bone regeneration within a single surgical strategy.
Elutiq collaborates with leading academic and clinical institutions including RWTH Aachen University and University Hospital Aachen. Early engagement with orthopedic surgeons and trauma centers in Europe and the United States supports clinical translation and alignment with real surgical workflows.
Elutiq merges nanomedicine and pharmacological technologies with clinically proven allograft biology to replace costly two-stage procedures with one-stage treatment where infection management and regeneration happen together.
US economy
Adoption is driven by total episode cost, not implant price. Elutiq is designed to reduce total episode cost by eliminating downstream procedures and operational inefficiencies.
Current treatment pathway
$6-10K
Adjunct material.
$25-45K
Staged procedures structural cost.
Operational inefficiency
OR time | LOS | Readmissions
$30-50K
Total episode cost.
$100-120K
Total cost range including revision/s
Elutiq single-stage platform
~$7.5K
Single procedure.
No staged procedures
Reduced OR time | Reduced LOS
Lower total episode cost
Operational efficiency can support hospital margin expansion.
No new reimbursement codes required
OsteoFlux™ is aligned within existing US MS-DRG.
Margin expansion is driven by operational efficiency, not reimbursement change.
The single-stage platform targets the downstream costs created by repeated procedures, length of stay, readmissions, and operating room inefficiency.
Latest news
Road-to Bio-Europe 2026 Grand Prize Winner - Gateway Factory
A Gateway Factory pitch competition with the support of Informa, for NRW based DeepTech/Biotech startups.
13 July 2026
Galaxy Community Award 2026 Winner
Recognized through the Galaxy startup community award program.
23 April 2026
Selected as a Top 12 MedTech Startup at Plug and Play 2026
Corporate-referred by Zimmer Biomet, with pitch activity at Zimmer Biomet's global headquarters.
03 April 2026
Partnered with Aachen University Hospital for prototype development
Collaborating with Prof. Dr. Dr. Twan Lammers' group to advance drug-eluting bone graft prototypes.
15 December 2025
1st Place at BioRiver Boost Competition
Winner of the 12th BioRiver Boost, one of Germany's premier industry-led Biotech/MedTech startup competitions.
11 December 2025
Top Prize at ZEBRA Accelerator
Awarded top prize in the Investment MasterClass category at the ZEBRA Accelerator program.
04 December 2025
State Innovative Entrepreneurs Grant Award
Dr. Wa'el Al Rawashdeh was awarded the State Innovative Entrepreneurs Grant to accelerate development of regenerative technologies.
01 October 2025
